Replies to post #22 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

>When do we see the results from the other arms of Prove-1? For some reason I thought we would get the first 20 patients from each arm at the same time.<

In the initial 80-patient randomization into four arms, only one of the arms (20 patients) is unblinded at 10 weeks. This is the arm whose initial treatment is VX-950+pegifn+ribavirin for only 12 weeks.

Two other PROVE-1 arms (40 patients combined) contain initial treatment with VX-950+pegifn+ribavirin for 24 weeks; these arms will be unblinded at 20 weeks, during 1Q07. (The only distinction between these two arms is how long the follow-up on SoC is for patients who are PCR-negative at both week 4 and week 20.)

The fourth arm in the initial 80-patient randomization is SoC only.

PROVE-1 will have a second randomization of 180 patients into each of the arms discussed above except the 12-week arm that is the one to report data this month.

Clear?

[DewDiligence]

Summary of PROVE-1 over/under guesses
for initial 20-patients randomization:

 
  
                            Gofish   Dew 
 PCR*-negative at 10 wks      95%    95% 
 SVR12**                      90%    80% 
 SVR**                        88%    70%

*TaqMan assay
**Based on original patient pool